These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 12960131)

  • 1. Peroxiredoxins in breast carcinoma.
    Karihtala P; Mäntyniemi A; Kang SW; Kinnula VL; Soini Y
    Clin Cancer Res; 2003 Aug; 9(9):3418-24. PubMed ID: 12960131
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Overexpression of peroxiredoxins I, II, III, V, and VI in malignant mesothelioma.
    Kinnula VL; Lehtonen S; Sormunen R; Kaarteenaho-Wiik R; Kang SW; Rhee SG; Soini Y
    J Pathol; 2002 Mar; 196(3):316-23. PubMed ID: 11857495
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Overexpression of peroxiredoxin in human breast cancer.
    Noh DY; Ahn SJ; Lee RA; Kim SW; Park IA; Chae HZ
    Anticancer Res; 2001; 21(3B):2085-90. PubMed ID: 11497302
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of neural cell types expressing peroxiredoxins in mouse brain.
    Jin MH; Lee YH; Kim JM; Sun HN; Moon EY; Shong MH; Kim SU; Lee SH; Lee TH; Yu DY; Lee DS
    Neurosci Lett; 2005 Jun; 381(3):252-7. PubMed ID: 15896479
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression of peroxiredoxin and thioredoxin in human lung cancer and paired normal lung.
    Park JH; Kim YS; Lee HL; Shim JY; Lee KS; Oh YJ; Shin SS; Choi YH; Park KJ; Park RW; Hwang SC
    Respirology; 2006 May; 11(3):269-75. PubMed ID: 16635084
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oxidative/nitrosative stress and peroxiredoxin 2 are associated with grade and prognosis of human renal carcinoma.
    Soini Y; Kallio JP; Hirvikoski P; Helin H; Kellokumpu-Lehtinen P; Kang SW; Tammela TL; Peltoniemi M; Martikainen PM; Kinnula VL
    APMIS; 2006 May; 114(5):329-37. PubMed ID: 16725008
    [TBL] [Abstract][Full Text] [Related]  

  • 7. LEA-135 expression: its association with a lower risk of recurrence and increased overall survival of patients with lymph node-positive primary invasive breast cancer.
    Saha B; Zhang N; Naritoku WY; Tsao-Wei DD; Groshen SL; Carlsson G; Larsson L; Gustavsson B; Chaiwun B; Taylor CR; Imam SA
    Anticancer Res; 2004; 24(4):2391-400. PubMed ID: 15330189
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Peroxiredoxin IV protects cells from radiation-induced apoptosis in head-and-neck squamous cell carcinoma.
    Park JJ; Chang HW; Jeong EJ; Roh JL; Choi SH; Jeon SY; Ko GH; Kim SY
    Int J Radiat Oncol Biol Phys; 2009 Mar; 73(4):1196-202. PubMed ID: 19251091
    [TBL] [Abstract][Full Text] [Related]  

  • 9. p53 status is a major determinant of effects of decreasing peroxiredoxin I expression on tumor growth and response of lung cancer cells to treatment.
    Chen MF; Chen WC; Wu CT; Lin PY; Shau H; Liao SK; Yang CT; Lee KD
    Int J Radiat Oncol Biol Phys; 2006 Dec; 66(5):1461-72. PubMed ID: 17084559
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Involvement of peroxiredoxin IV in the 16alpha-hydroxyestrone-induced proliferation of human MCF-7 breast cancer cells.
    Lee SU; Rhee Mc; Min YK; Kim SH
    Cell Biol Int; 2008 Apr; 32(4):401-5. PubMed ID: 18272409
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression of matrix metalloproteinase (MMP)-2 and MMP-9 in breast cancer with a special reference to activator protein-2, HER2, and prognosis.
    Pellikainen JM; Ropponen KM; Kataja VV; Kellokoski JK; Eskelinen MJ; Kosma VM
    Clin Cancer Res; 2004 Nov; 10(22):7621-8. PubMed ID: 15569994
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Altered expression of metastasis-associated and regulatory molecules in effusions from breast cancer patients: a novel model for tumor progression.
    Davidson B; Konstantinovsky S; Nielsen S; Dong HP; Berner A; Vyberg M; Reich R
    Clin Cancer Res; 2004 Nov; 10(21):7335-46. PubMed ID: 15534110
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Flt-4-positive vessel density correlates with vascular endothelial growth factor-d expression, nodal status, and prognosis in breast cancer.
    Nakamura Y; Yasuoka H; Tsujimoto M; Yang Q; Imabun S; Nakahara M; Nakao K; Nakamura M; Mori I; Kakudo K
    Clin Cancer Res; 2003 Nov; 9(14):5313-7. PubMed ID: 14614015
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Human epidermal growth factor receptor 2 status correlates with lymph node involvement in patients with estrogen receptor (ER) negative, but with grade in those with ER-positive early-stage breast cancer suitable for cytotoxic chemotherapy.
    Bartlett JM; Ellis IO; Dowsett M; Mallon EA; Cameron DA; Johnston S; Hall E; A'Hern R; Peckitt C; Bliss JM; Johnson L; Barrett-Lee P; Ellis P
    J Clin Oncol; 2007 Oct; 25(28):4423-30. PubMed ID: 17906205
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High-level SLP-2 expression and HER-2/neu protein expression are associated with decreased breast cancer patient survival.
    Cao W; Zhang B; Liu Y; Li H; Zhang S; Fu L; Niu Y; Ning L; Cao X; Liu Z; Sun B
    Am J Clin Pathol; 2007 Sep; 128(3):430-6. PubMed ID: 17709317
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mouse peroxiredoxin V is a thioredoxin peroxidase that inhibits p53-induced apoptosis.
    Zhou Y; Kok KH; Chun AC; Wong CM; Wu HW; Lin MC; Fung PC; Kung H; Jin DY
    Biochem Biophys Res Commun; 2000 Feb; 268(3):921-7. PubMed ID: 10679306
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antisense of human peroxiredoxin II enhances radiation-induced cell death.
    Park SH; Chung YM; Lee YS; Kim HJ; Kim JS; Chae HZ; Yoo YD
    Clin Cancer Res; 2000 Dec; 6(12):4915-20. PubMed ID: 11156252
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of extracellular matrix and apoptotic markers between benign lesions and carcinomas in human breast.
    Vasaturo F; Sallusti E; Gradilone A; Malacrino C; Nardo T; Avagnano G; Aglianò AM; Granato T; De Vincenzi B; Coppotelli G; Marzullo A; Soda G; Simonelli L; Modesti M; Scarpa S
    Int J Oncol; 2005 Oct; 27(4):1005-11. PubMed ID: 16142317
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increased expression of peroxiredoxin II confers resistance to cisplatin.
    Chung YM; Yoo YD; Park JK; Kim YT; Kim HJ
    Anticancer Res; 2001; 21(2A):1129-33. PubMed ID: 11396151
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Peroxiredoxin I and II inhibit H2O2-induced cell death in MCF-7 cell lines.
    Bae JY; Ahn SJ; Han W; Noh DY
    J Cell Biochem; 2007 Jul; 101(4):1038-45. PubMed ID: 17163455
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.